SS
IMNM icon

SBI Securities’s Immunome IMNM Stock Holding History

SBI Securities’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$350 Buy
16
+7
+78% +$156 ﹤0.01% 3021
2025
Q4 		$193 Sell
9
-14
-61% -$246 ﹤0.01% 3221
2025
Q3 		$269 Sell
23
-47
-67% -$468 ﹤0.01% 3219
2025
Q2 		$651 Buy
70
+20
+40% +$164 ﹤0.01% 2853
2025
Q1 		$337 Buy
50
+26
+108% +$249 ﹤0.01% 3024
2024
Q4 		$255 Buy
+24
New +$290 ﹤0.01% 3156

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

SBI Securities's IMNM Position: Q1 2026 in Review

SBI Securities increased its Immunome (IMNM) stake by 78% in Q1 2026, buying an estimated $156 and bringing the position to 16 shares worth $350. The position accounts for ﹤0.01% of the portfolio, ranked #3021.

SBI Securities first reported a position in IMNM in Q4 2024 and has held it in 6 quarters since. The position peaked at $651 in Q2 2025. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • SBI Securities held 16 shares of Immunome worth $350 as of Q1 2026.
  • SBI Securities bought 7 Immunome shares in Q1 2026, an estimated $156.
  • Immunome made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #3021 holding.
  • SBI Securities first reported a position in Immunome in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Immunome position peaked at $651 in Q2 2025.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.